Analysis of exit interviews shows benefits of LX 1032 (telotristat etiprate) in carcinoid syndrome- Lexicon Pharmaceuticals

LX 1032 (telotristat etiprate), from Lexicon Pharmaceuticals, for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional wellbeing according to new exit interview data from the Phase III TELESTAR study. Telotristat etiprate met the study's primary endpoint with clinically meaningful reductions in bowel movement frequency in cancer patients whose carcinoid syndrome was not adequately controlled by somatostatin analog (SSA) therapy.

New data released from interviews with participating patients who completed the randomised treatment portion of the TELESTAR study demonstrated that these reductions were meaningful to those patients and led to improvements in social and physical function and emotional wellbeing. The 12-week study period is being followed by a 36-week open-label extension where all patients receive telotristat etiprate 500 mg three times daily. Data were presented at the 2015 Neuroendocrine Tumor Society Annual Symposium.